Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F22%3A00559932" target="_blank" >RIV/61388963:_____/22:00559932 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/22:73613769
Result on the web
<a href="https://worldwide.espacenet.com/patent/search/family/056550662/publication/EP3478701B1?q=EP3478701B1" target="_blank" >https://worldwide.espacenet.com/patent/search/family/056550662/publication/EP3478701B1?q=EP3478701B1</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
Original language description
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use The invention provides a new group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, wherein R is defined in the claims. The compounds of this invention show strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.
Czech name
—
Czech description
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID
EP3478701
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Aug 10, 2022
Owner name
Ústav organické chemie a biochemie AV ČR, v. v. i. – Univerzita Palackého v Olomouci
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence

Similar results(10)